Results 61 to 70 of about 2,198 (193)
FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022 [PDF]
, 2023 The inclusion of fluorine atoms or heterocyclic moiety into drug structures represents a recurrent motif in medicinal chemistry. The combination of these two features is constantly appearing in new molecular entities with various biological activities ...
Amata S. +5 more
core +1 more source
Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy [PDF]
, 2023 The RET (REarranged during Transfection) gene, which encodes for a transmembrane receptor tyrosine kinase, is an established oncogene associated with the etiology and progression of multiple types of cancer.
Basilaia, Mariam +5 more
core +1 more source
High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial. [PDF]
, 2023 This paper presents results from Cohort B (rearranged during transfection [RET], fusion-positive) of the Blood First Assay Screening Trial in patients with advanced non-small cell lung cancer (NSCLC) screened for genetic alterations using blood-based ...
Aix, S.P. +13 more
core +1 more source
Precious Gene: The Application of RET-Altered Inhibitors
Molecules, 2022 The well-known proto-oncogene rearrangement during transfection (RET), also known as ret proto-oncogene Homo sapiens (human), is a rare gene that is involved in the physiological development of some organ systems and can activate various cancers, such as
Qitao Gou +4 more
doaj +1 more source
Innovations in the systemic treatment of medullary thyroid cancer with kinase inhibitors [PDF]
, 2023 Introduction: Medullary thyroid carcinoma is a primary thyroid neoplasm originating from thyroid C cells. It can be familial or sporadic. The familial form is associated with multiple endocrine neoplasia (MEN) syndrome types 2A and 2B and is caused by a ...
Jasiura, Adam +7 more
core +1 more source
Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs
Clinical Pharmacology &Therapeutics, EarlyView.Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri +10 more
wiley +1 more source
Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion-Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting [PDF]
Purpose: RET fusions are oncogenic drivers across different solid tumors. However, the genomic landscape and natural history of patients with RET fusion-positive solid tumors are not well known.
Bordogna, Walter +8 more
core +4 more sources
Head &Neck, EarlyView.ABSTRACT Background Brain metastases (BM) of differentiated thyroid carcinoma (DTC) are associated with unfavorable prognosis. This study evaluated BM management strategies and patients' outcomes. Methods A retrospective review of patients diagnosed with DTC and BM at Tel Aviv Sourasky and Rabin Medical Centers between 1985 and 2024. Clinical features,
Liyona Kampel +9 more
wiley +1 more source
Med Research, EarlyView.ABSTRACT Molecular diagnostics have become an important adjunct to ultrasonography and fine‐needle aspiration (FNA) for thyroid nodules, especially in Bethesda III/IV cytology where malignancy risk is uncertain. This narrative review summarizes the diagnostic and prognostic value of key genomic drivers (BRAF V600E, RAS, RET, TERT, and selected fusions)
Guohui Xiao +14 more
wiley +1 more source
Journal of Molecular Pathology, 2022 RET alterations are recognized as key oncogenic drivers in different cancer types, including non-small cell lung cancer (NSCLC). Multikinase inhibitors (MKIs) with anti-RET activities resulted in variable efficacy with significant toxicities because of ...
Maria Lucia Reale +4 more
doaj +1 more source